Parkinson's Disease

Introduction

Parkinson's Disease Handout

Name of Disorder: Parkinson's Disease

Clinical Information

The following data is from validated clinical sources and patient registries.

Core Characteristics

• Etiology: Variable
• Pathology: Ideopathic
• Rarity Classification: High
• Typical Onset: Adulthood
• Gender Impact: Either Gender
• Progressive/Degenerative: Yes
• Seizure Prevalence: No (<10%)
• Population Trend: Stable

Pathophysiology

Genetic factors are pretty rare; environmental issues could be in play, but research is particularly focusing on Lewy bodies and alpha-synuclein within them specifically.

AAC Considerations

Recommended Access Modalities: All - Progression

Additional Clinical Notes

The value of this market is extremely high, which is true, but also somewhat misleading because the calculation is based on end-stage needs and ASP, and eye gaze reliance in Parkinsons can be a brief period for many people

Formal Name: Parkinson's Disease (PD)

Demographic Information:

• Incidence: Approximately 1 in 100 people over the age of 60
• Prevalence: About 1% of the population over 60 years old
• Gender: More common in men than women
• Onset Age: Typically between 55 and 65 years old, though early-onset Parkinson's can occur before the age of 50

Coding:

• ICD-11: 8A00
• ICD-10-CM: G20
• OMIM: 168600
• UMLS: C0030567
• MeSH: D010300
• GARD: 7251

Quick Reference

Medical Features and Pathophysiology:

• Etiology: Parkinson's Disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the substantia nigra, a region of the brain that controls movement. The exact cause of PD is unknown, but it is believed to involve a combination of genetic and environmental factors. Mutations in specific genes, such as LRRK2, PARK7, PINK1, PRKN, and SNCA, have been associated with familial forms of the disease. Environmental factors, such as exposure to pesticides and heavy metals, are also thought to contribute to the risk of developing PD.
• Pathology: The hallmark pathological feature of PD is the presence of Lewy bodies, which are abnormal aggregates of the protein alpha-synuclein, within neurons. These Lewy bodies disrupt normal cellular function and lead to the death of dopamine-producing neurons. The loss of dopamine in the basal ganglia, a brain region involved in controlling movement, results in the characteristic motor symptoms of PD. Additionally, non-motor symptoms, such as cognitive impairment and psychiatric disturbances, may occur due to the involvement of other neurotransmitter systems.
• Symptoms:
  • Motor Symptoms:
    • Tremor at rest (often described as "pill-rolling" tremor)
    • Bradykinesia (slowness of movement)
    • Rigidity (muscle stiffness)
    • Postural instability (impaired balance and coordination)
  • Non-Motor Symptoms:
    • Cognitive impairment and dementia
    • Psychiatric symptoms (depression, anxiety, hallucinations, and psychosis)
    • Autonomic dysfunction (constipation, orthostatic hypotension, urinary incontinence)
    • Sleep disturbances (REM sleep behavior disorder, insomnia)
• Diagnosis: Diagnosis of PD is primarily clinical, based on the presence of characteristic motor symptoms and response to dopaminergic therapy. Imaging studies, such as dopamine transporter (DAT) scans, can support the diagnosis by demonstrating reduced dopamine activity in the basal ganglia. Genetic testing may be considered in cases with a family history of PD or early-onset disease.

Assistive Suggestions and Requirements:

• Requirement Percentage for Assistive Technology: A significant percentage of individuals with PD will benefit from assistive technology, particularly as the disease progresses and motor symptoms become more disabling.
• Assistive Technology Suggestions:
  • Mobility Aids:
    • Canes or Walkers: To assist with balance and prevent falls.
    • Wheelchairs: For individuals with severe mobility impairments.
  • Communication Aids:
    • Voice Amplifiers: To assist with hypophonia (soft speech).
    • Speech Generating Devices (SGDs): For individuals with severe speech difficulties.
  • Home Modifications:
    • Grab Bars and Handrails: To enhance safety and prevent falls.
    • Adjustable Beds: To improve comfort and ease of movement.
  • Feeding Aids:
    • Adaptive Utensils: For individuals with tremor or reduced hand dexterity.
• Access Modalities:
  • Switch Access: For individuals with severe motor impairments to control communication devices and computers.
  • Voice-Controlled Systems: Beneficial for those who retain good vocal strength.
  • Touchscreen Devices: Useful for those with adequate hand dexterity.

Care Management and Therapeutic Techniques:

• Aims:
  • To manage symptoms and maintain the highest possible level of independence and quality of life.
  • To provide supportive care and address complications through a multidisciplinary approach.
  • To offer education and support to patients and caregivers.
• SLP Suggestions:
  • Assessment and Intervention:
    • Regular speech and swallowing assessments to monitor changes and adjust therapy plans accordingly.
    • Techniques to improve speech clarity and address hypophonia (soft speech).
    • Swallowing techniques to ensure safe swallowing and reduce the risk of aspiration.
  • Augmentative and Alternative Communication (AAC):
    • Introduction of AAC devices early in the disease progression to ensure familiarity and ease of use as the disease progresses.
• Special Educator Suggestions:
  • Cognitive Rehabilitation:
    • Activities designed to enhance executive function, memory, and attention.
    • Use of memory aids, such as notebooks or electronic organizers.
  • Behavioral Strategies:
    • Structured routines to manage apathy and maintain engagement in activities.
    • Positive reinforcement to encourage participation and effort in tasks.
• Occupational Therapist Suggestions:
  • Daily Living Skills:
    • Training in the use of adaptive equipment for self-care activities (e.g., dressing, grooming).
    • Techniques to conserve energy and manage fatigue.
  • Home and Environmental Modifications:
    • Assessing and modifying the home environment to ensure safety and accessibility.
    • Recommendations for ergonomic furniture and tools to support independence.

Recommendations on AAC and Other Details:

• Text-Based AAC:
  • Use of text-to-speech apps and devices for individuals who retain good literacy skills.
  • Predictive text features to speed up communication.
• Symbol-Based AAC:
  • For individuals with cognitive impairments affecting literacy, symbol-based systems like Picture Communication Symbols (PCS) can be useful.
  • Dynamic display devices that can grow with the user’s needs.

Additional Information:

PD management requires a multidisciplinary approach balancing pharmacological and non-pharmacological interventions. Levodopa remains the most effective symptomatic treatment, though long-term use leads to motor complications including dyskinesias and wearing-off phenomena. Dopamine agonists, MAO-B inhibitors, and COMT inhibitors provide additional therapeutic options. Deep brain stimulation effectively manages motor fluctuations in advanced disease.

Non-motor symptoms often prove more disabling than motor features. Cognitive decline, psychiatric disturbances, autonomic dysfunction, and sleep disorders require targeted assessment and management. Physical therapy maintains mobility and reduces fall risk, while speech therapy addresses hypophonia and swallowing difficulties. Occupational therapy supports independence in activities of daily living.

Research continues to explore disease-modifying therapies, biomarkers for early diagnosis, and treatments targeting alpha-synuclein pathology. Support organizations and advocacy groups provide essential resources for individuals and families navigating this progressive condition.

References

1. Jankovic, J. (2008). Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 79(4), 368-376.
2. Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896-912.
3. Schapira, A. H. V. (2009). Neurobiology and treatment of Parkinson's disease. Neurology, 72(21 Supplement 4), S1-S136.

Epidemiology and Demographics

Etiology and Pathophysiology

Clinical Features and Stages

Diagnosis

Clinical Recommendations

Care Management

Transition Planning